Penggunaan Antivirus untuk COVID-19
DOI:
https://doi.org/10.55175/cdk.v48i7.100Keywords:
antivirus, COVID-19, ebola, influenzaAbstract
Corona Disease 2019 (COVID-19) ditetapkan sebagai pandemi pada Maret 2020. Hingga saat ini belum ada terapi yang tepat untuk mencegah dan mengobati COVID-19. Beberapa antivirus diteliti sebagai profilaksis dan terapi COVID-19, seperti Hydroxychloroquine, Chloroquine, Lopinavir/Ritonavir, Baloxavir, Umifenovir, Remdesivir, Favipiravir, Oseltamivir, Molnupiravir, dan AT527.
Corona Disease 2019 (COVID-19) was declared a pandemic in March 2020. Until now, there is no appropriate therapy to prevent and treat COVID-19. Several antivirals are being studied as prophylaxis and treat COVID-19, including: Hydroxychloroquine, Chloroquine, Lopinavir/Ritonavir, Baloxavir, Umifenovir, Remdesivir, Favipiravir, Oseltamivir, Molnupiravir, and AT527.
Downloads
References
WHO Timeline - COVID-19 [Internet]. [cited 2021 Mar 28]. Available from: https://www.who.int/news/item/27-04-2020-who-timeline---covid-19
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020 Mar 1;55(3):105924.
National Institutes of Health. COVID-19 treatment guidelines. Antiviral therapy [Internet]. [cited 2021 Mar 28]. Available from: https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/
Pedoman tatalaksana COVID-19 edisi 3 (Desember 2020) [Internet]. [cited 2021 Mar 29]. Available from: https://www.papdi.or.id/download/983-pedomantatalaksana-covid-19-edisi-3-desember-2020
PINHO AC. COVID-19 treatments. European Medicines Agency [Internet]. 2021 [cited 2021 Apr 19]. Available from: https://www.ema.europa.eu/en/humanregulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-treatments
IDSA Home [Internet]. [cited 2021 Apr 19]. Available from: https://www.idsociety.org/
Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19? Int J Antimicrob Agents. 2020 May 1;55(5):105938.
Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention | Global Health | JAMA | JAMA Network [Internet]. [cited 2021 Mar 28]. Available from: https://jamanetwork.com/journals/jama/fullarticle/2762130
Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection: A randomized clinical trial - PubMed [Internet]. [cited 2021 Mar 28]. Available from: https://pubmed.ncbi.nlm.nih.gov/32330277/
Magagnoli J, Narendran S, Pereira F, Cummings TH, Hardin JW, Sutton SS, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. Med N Y N. 2020 Dec 18;1(1):114-127.e3.
Repurposed antiviral drugs for Covid-19 — Interim WHO solidarity trial results. N Engl J Med [Internet]. 2020 Dec 2 [cited 2021 Mar 28]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727327/
Mitjà O, Corbacho-Monné M, Ubals M, Tebe C, Peñafiel J, Tobias A, et al. Hydroxychloroquine for early treatment of adults with mild Covid-19: A randomizedcontrolled trial. Clin Infect Dis Off Publ Infect Dis Soc Am [Internet]. 2020 Jul 16 [cited 2021 Mar 28]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454406/
Rajasingham R, Bangdiwala AS, Nicol MR, Skipper CP, Pastick KA, Axelrod ML, et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: A randomized trial. Clin Infect Dis Off Publ Infect Dis Soc Am [Internet]. 2020 Oct 17 [cited 2021 Mar 28]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665393/
Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19. Ann Intern Med [Internet]. 2020 Jul 16 [cited 2021 Mar 28]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384270/
National Institutes of Health. COVID-19 treatment guidelines. Chloroquine or hydroxychloroquine [Internet]. 2020 [cited 2021 Mar 28]. Available from: https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/chloroquine-or-hydroxychloroquine-with-or-without-azithromycin/
Sisay M. 3CLpro inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials. Pharmacol Res. 2020 Jun;156:104779.
Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: A review. Ther Clin Risk Manag. 2008 Oct;4(5):1023–33.
WHO | Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection [Internet]. [cited 2021 May 11]. Available from: https://www.who.int/hiv/pub/guidelines/arv2013/en/
Meynard JL, Moinot L, Landman R, Morand-Joubert L, Besseghir A, Kolta S, et al. Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: A randomized non-inferiority trial (ANRS 140 DREAM). J Antimicrob Chemother. 2018 Jun 1;73(6):1672–6.
Su B, Wang Y, Zhou R, Jiang T, Zhang H, Li Z, et al. Efficacy and tolerability of lopinavir/ritonavir- and efavirenz-based initial antiretroviral therapy in HIV-1-infected patients in a tertiary care hospital in Beijing, China. Front Pharmacol. 2019;10:1472.
Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. The Lancet. 2020 Oct;396(10259):1345–52.
National Institutes of Health. COVID-19 treatment guidelines. Lopinavir/ritonavir and other HIV protease inhibitors [Internet]. [cited 2021 Mar 28]. Available from: https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/lopinavir-ritonavir-and-other-hiv-protease-inhibitors/
CDC. Influenza antiviral drug baloxavir marboxil [Internet]. 2020 [cited 2021 Mar 29]. Available from: https://www.cdc.gov/flu/treatment/baloxavir-marboxil.htm
Baker J, Block SL, Matharu B, Burleigh Macutkiewicz L, Wildum S, Dimonaco S, et al. Baloxavir marboxil single-dose treatment in influenza-infected children: A randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2). Pediatr Infect Dis J. 2020 Aug;39(8):700–5.
Ison MG, Portsmouth S, Yoshida Y, Shishido T, Mitchener M, Tsuchiya K, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): A randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020 Oct 1;20(10):1204–14.
Lou Y, Liu L, Yao H, Hu X, Su J, Xu K, et al. Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: An exploratory randomized, controlled trial. Eur J Pharm Sci. 2021 Feb 1;157:105631.
Proskurnina EV, Izmailov DYu, Sozarukova MM, Zhuravleva TA, Leneva IA, Poromov AA. Antioxidant potential of antiviral drug umifenovir. Molecules [Internet]. 2020 Mar 30 [cited 2021 Mar 29];25(7). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181215/
Pshenichnaya N, Bulgakova V, Selkova E, Maleyev V, Lvov N, Leneva I, et al. Umifenovir in treatment of influenza and acute respiratory viral infections in outpatient care. Int J Infect Dis. 2019 Feb 1;79:103.
Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis.J Med Virol [Internet]. 2020 Jul 14 [cited 2021 Mar 29]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361300/
Oseltamivir - an overview | ScienceDirect Topics [Internet]. [cited 2021 May 11]. Available from: https://www.sciencedirect.com/topics/medicine-and-dentistry/oseltamivir
CDC. Influenza antiviral medications: Clinician summary [Internet]. 2021 [cited 2021 Mar 29]. Available from: https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm
Li M, Han G, Chen Y, Du W, Liu F, Chi Y, et al. Efficacy of oseltamivir compared with zanamivir in COPD patients with seasonal influenza virus infection: A randomized controlled trial. Braz J Med Biol Res. 2021;54(2):e9542.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet Lond Engl. 2020;395(10223):507–13.
Tan Q, Duan L, Ma Y, Wu F, Huang Q, Mao K, et al. Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study. Bioorganic Chem. 2020 Nov;104:104257.
Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020 Apr 21;50(SI-1):611–9.
Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, et al. Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection. J Infect Dis. 2020 Apr 27;221(10):1688–98.
Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): A historically controlled, single-arm proof-of-concept trial in Guinea [Internet]. [cited 2021 May 11]. Available from: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001967
Łagocka R, Dziedziejko V, Kłos P, Pawlik A. Favipiravir in therapy of viral infections. J Clin Med. 2021 Jan;10(2):273.
Udwadia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-tomoderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021 Feb;103:62–71.
Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, et al. AVIFAVIR for treatment of patients with moderate COVID-19: Interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis Off Publ Infect Dis Soc Am [Internet]. 2020 Aug 9 [cited 2021 Mar 29]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454388/
nstiaty, Darmayani IGAAPS, Marzuki JE, Angelia F, William, Siane A, et al. Antiviral treatment of COVID-19: A clinical pharmacology narrative review. Med J Indones.2020 Jul 18;29(3):332–45.
Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus arbidol for COVID-19: A randomized clinical trial. medRxiv. 2020 Apr 15;2020.03.17.20037432.
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: An Open-Label Control Study. Eng Beijing China. 2020 Oct;6(10):1192–8.
Pardo J, Shukla AM, Chamarthi G, Gupte A. The journey of remdesivir: From Ebola to COVID-19. Drugs Context. 2020 May 22;9:1–9.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - Final report. N Engl J Med. 2020 Nov 5;383(19):1813–26.
Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. JAMA. 2020 Sep 15;324(11):1–10.
Gilead presents additional data on investigational antiviral remdesivir for the treatment of COVID-19 [Internet]. [cited 2021 Mar 29]. Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/gilead-presents-additional-data-on-investigational-antiviral-remdesivir-for-the-treatment-ofcovid-19
FDA. Research C for DE and. FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—The Science of Safety and Effectiveness [Internet]. 2020 Oct 22 [cited 2021 Mar 29]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safetyand-effectiveness
Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med [Internet]. 2020 Apr 6 [cited 2021 May 11]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164393/
Painter GR, Bowen RA, Bluemling GR, DeBergh J, Edpuganti V, Gruddanti PR, et al. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Res. 2019 Nov 1;171:104597.
Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother. 2021 Mar 1;AAC.02428-20, aac;AAC.02428-20v1.
Abdelnabi R, Foo CS, Kaptein SJF, Zhang X, Langendries L, Vangeel L, et al. Molnupiravir (EIDD-2801) inhibits SARS-CoV2 replication in Syrian hamsters model. bioRxiv. 2020 Dec 10;2020.12.10.419242.
Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol. 2021 Jan;6(1):11–8.
Good SS, Moussa A, Zhou XJ, Pietropaolo K, Sommadossi J-P. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. PLOS ONE. 2020 Jan 8;15(1):e0227104.
Good SS, Westover J, Jung KH, Colla PL, Collu G, Moussa A, et al. AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic. bioRxiv. 2020 Aug 11;2020.08.11.242834.
Clinical trial on COVID-19: AT-527, placebo - Clinical trials registry - ICH GCP [Internet]. [cited 2021 Mar 21]. Available from: https://ichgcp.net/clinical-trials-registry/NCT04396106
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Cermin Dunia Kedokteran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
